Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DoubLNG: Increased Dose Levonorgestrel Implant with Efavirenz in HIV
NCT02722421Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- Apr 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avatrombopag in contraception, sponsored by University of Nebraska. Primary endpoint: Levonorgestrel plasma concentrations at 24 weeks. Started Apr 2017; status: completed.
02
Drugs
avatrombopag
03
Conditions
contraception
Beyond the preview
Go deeper on NCT02722421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722421.